This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Treatment and outcomes for Peters anomaly (PA)

Treatment and outcomes for Peters anomaly (PA)
Reviewed by Fiona Rowe

5 August 2022 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus
Share This

The purpose of this study was to evaluate the experience of patients with Peters anomaly (PA) and their treatment results. The study reviewed records of 27 patients (32 eyes); 74% male. Treatment included medical follow-up, optical iridectomy and penetrating keratoplasty with or without lensectomy / vitrectomy for type I PA. Type II treatment included penetrating keratoplasty, lensectomy and anterior vitrectomy. All were treated for amblyopia. Five patients were bilateral and 22 were unilateral. Average age at first assessment was 57.62 days (median 39 days). Average age at first surgery was 151 days (median 103). Average follow-up was 10.2 years. Pre and post IOP was 22 ±7.87mmHg and 21 ±10.61mmHg respectively. If IOP was >25mm, patients were given topical hypotensive glaucoma treatment. Fifteen patients (17 eyes) were type I and 12 (15 eyes) were type II. Overall visual acuity results were 1.71 ±1.04 logMAR. Type I; 0.30 ±0.00 logMAR with medical treatment, 0.97 ±0.78 with peripheral iridectomy and 1.22 ±0.97 with penetrating keratoplasty. Type II; 2.41 ±0.80 logMAR without posterior pole compromise and 2.56 ±0.48 with posterior pole compromise. Type I had a 50% graft failure: 55% failure in type II without posterior pole compromise and 75% in type II with posterior pole compromise. The authors suggest surgical management should always be offered for a compromised eye due to severity of the anomaly and to offer a chance of improved visual function. They propose an assessment and management scheme for these patients dependent on type and associated characteristics.

Long-term experience and visual acuity outcomes in patients with Peters anomaly.
Rojas RD, Urrutia GJ, Lopez Garin JP.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2021;58:304-10.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency